Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

3,4-Dimethoxybenzoic acid (100 mg, 0.55 mmol) was dissolved in DMF (1 mL). EDC (124.6 mg, 0.65 mmol) and HOBt (81 mg, 0.6 mmol) were added, followed by N- methylmorpholine (0.71 mL, 0.65 mmol). The resulting solution was agitated for 1 h. 3- Aminomethylphenyl-carbamic acid tert-butyl ester (111 mg, 0.5 mmol) was then added and the resulting mixture was agitated overnight. The reaction mixture was diluted with 4 mL dichloromethane, and the resulting mixture was washed with 1 N HCl (2 x 5 mL), NaHCO3 (saturated aqueous, 2 x 5 mL), and brine (1 x 5 mL), dried, and the solvents were evaporated to provide 190 mg (quantitative yield) of (3-[(3,4-dimethoxy-benzoylamino)- methyl]-phenyl}-carbamic acid tert-butyi ester, which was dissolved in dichloromethane (2 mL). SCX (1.14 g, 1.0 mmol) was added and the resulting mixture was agitated for 48 h. The reaction mixture was filtered and the solids were washed with dichloromethane (2 x 2 mL) and methanol (2 x 2 mL). The product was eluted with NH3 in methanol (7 N, 2 x 2 mL). The solvents were evaporated to provide 112 mg (78% yield) of 7V-(3-amino- benzyl)-3,4-dimethoxy-benzamide as a white solid, which was used directly. 3,4-Dihydro- lH-isoquinoline-2,6-dicarboxylic acid 2-tert-buty{ ester (19.1 mg, 0.069 mmol), EDC (19.2 mg, 0.1 mmol), and HOBt (12.2 mg, 0.09 mmol) were combined in a reaction tube, and DMF (1 mL) was added. To the resulting solution was added N-methylmorpholine (0.013 mL, 0.12 mmol), and the mixture was agitated for 1 h. The intermediate prepared above, Lambda/-(3-amino-benzyl)-3,4-dimethoxy-benzamide (17 mg, 0.059 mmol), was then added as a solution in DMF (0.3 mL), and the reaction mixture was agitated overnight. The reaction mixture was diluted with 6 mL dichloromethane, and the resulting mixture was washed with 1 N HCl (2 x 2 mL), NaHCO3 (saturated aqueous, 2 x 2 mL), and brine (1 x 2 mL), dried, and concentrated to 32 mg of 6-{3-[(3,4-dimethoxy-benzoylamino)- methyl]-phenylcarbamoyl}-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester as an oil, which was redissolved in dichloromethane (1 mL) and treated with SCX (284 mg, 0.25 mmol). The resulting mixture was agitated overnight. The reaction mixture was filtered and the solids were washed with dichloromethane (2 x 2 mL) and methanol (2 x 2 mL). The product was eluted with NH3 in methanol (7 N, 2 x 2 mL), and the eluant was evaporated. The resulting residue was purified by preparative HPLC using an acetonitrile/water/formic acid gradient providing the title compound as a formate salt (20 mg, 77% yield – 2 steps), MS analysis electrospray, 446 (M+H)., 170097-67-3

As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; WO2008/86047; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3,170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate 9: 1 ,1-dimethylethyl 6-({ri-({5-chloro-2-r(2-methylpropyl)oxylphenyl}methyl)-5- ethyl-I H-pyrazol-S-yliaminolcarbonvD-S^-dihydro^d l-D-isoquinolinecarboxylate; To a solution of 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-ethyl-1 H-pyrazol-3- amine (Intermediate 7) (0.5 g, 1.62 mmol) in DMF (1 OmL) was added 2-{[(1 ,1- dimethylethyOoxylcarbonylJ-I ^.S^-tetrahydro-theta-isoquinolinecarboxylic acid (0.41 g, 0.9 eq.), HATU (0.74 g, 1.2 eq.) and DIEA (0.34 ml_,1.2 eq.) and the mixture was stirred at room temperature for 24 hours. The solvent was evaporated under reduced pressure and the residue was diluted with DCM. The organic phase was then washed with water and dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM/EtOAc: 95/5 to give the title compound as an oil (120 mg, 13%). LC/MS: m/z 567 (M+H)+ Rt: 4.23 min.

170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acidbelongs to tetrahydroisoquinoline compound, is more and more widely used in various fields. and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/74834; (2008); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

151838-62-9, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of Boc-Tic-OH (0.33 g, 1.20 mmol) and 2TFAH2N-CH[(CH2)4-NH- Z]-Bid [benzyl 5-amino-5-(lH-benzo[151838-62-9, As the paragraph descriping shows that 151838-62-9 is playing an increasingly important role.

Reference£º
Patent; GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2008/16913; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

215798-19-9, 6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,215798-19-9

A suspension of 6-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride (CASNo.226942-29-6 , commercially available from Allichem LLC, 1 g, 4.02 mmol) and di-tert- butyl dicarbonate (1.87 ml, 8.05 mmol) in MeOH (10 ml) at room temperature under nitrogen was treated with triethylamine (2.80 ml, 20.12 mmol) and the resulting mixture was stirred at room temperature for 20 hours then concentrated in vacuo.The residue was partitioned between DCM and a saturated Na2CO3 aqueous solution and the two layers were separated using a phase separator cartridge. The organic phase was concentrated in vacuo and the residue loaded on a SCX column, eluting with MeOH. The combined methanolic fractions were concentrated in vacuo to give 1,1-dimethylethyl 6-bromo-3,4-dihydro-2(1H)-isoquinolinecarboxylate (1.215 g,97%) as a pale yellow gum.LCMS: retention time 1.38 min ; [M+H]+ = 314.02 (1 Br)

As the paragraph descriping shows that 215798-19-9 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; SMETHURST, Christian, Alan, Paul; DEMONT, Emmanuel, Hubert; LIN, Xichen; REN, Feng; BAILEY, James, Matthew; WO2010/145202; (2010); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-(tert-Butoxycarbonyl)- 1,2,3 ,4-tetrahydroisoquinoline-6-carboxylic acid (100 mg, 0.361 mmol) was dissolved in THF (5 mL) in an oven dried flask at -78 C. TMEDA (0.174 mL, 1.15 mmol) was added, followed by dropwise addition of a 1.6 M solution of n-BuLi in hexane (0.721 mL, 1.15 mmol) over 1 mm. The reaction mixture was stirred at-78 C for 1 hour, then a solution of Mel (0.090 mL, 1.4 mmol) dissolved in 1 mL of THFwas added. The reaction was allowed to warm to rt, and stirring was continued at rt for 45minutes. The reaction was then quenched with an aq. solution of saturated NH4C1 and extracted 3x with EtOAc. The combined organic extracts were dried with Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography to provide 181A(70 mg, 67% yield), as a white solid. MS(ESI)m/z 290.1 (M-H)., 170097-67-3

As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; SMALLHEER, Joanne, M.; SHAW, Scott, A.; HALPERN, Oz, Scott; HU, Carol, Hui; KICK, Ellen, K.; (311 pag.)WO2017/40449; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22990-19-8,1-Phenyl-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,22990-19-8

Optically active (S)-mandelic acid (0.5 equiv) was added to the solution of racemic compound 5 (1.0 equiv) in mixture of toluene and methanol solvents at room temperature. The resulting suspension was stirred at 80 C to make homogeneous reaction mixture. The stirring was continued with heating at 80 C until completion of reaction. It was found that after 30 min the reaction was completed. The solution was allowed to cool to room temperature. Mandelic acid resolves diastereomeric mixture to S-form of 5, which was filtered from the solution. The filter cake was washed once with toluene and air-dried to yield compound 6 (S-form) as a white solid in 47 % yield. Compound 6 was treated with 2 M Sodium hydroxide solution and the toluene was added. Two layers were separated. Toluene fraction was dried over anhydrous Na2SO4, concentrated and purified on silica gel column (eluted using mixture of hexane and ethyl acetate) to obtain pure S-isomer.

As the paragraph descriping shows that 22990-19-8 is playing an increasingly important role.

Reference£º
Article; Krishna Rao; Surendra Babu; Basaveswara Rao; Keshavi; Sundara Rao; Eswara Prasad; Murthy; Asian Journal of Chemistry; vol. 29; 5; (2017); p. 1035 – 1038;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

923591-51-9, 5-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,923591-51-9

Intermediate O: 5-(2-(l-Methyl-lH-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-l,2,3,4- tetrahydroisoquinoline A vial was charged with 5-bromo-l,2,3,4-tetrahydroisoquinoline hydrochloride (ASW Medchem, Brunswick, NJ, 400.42 mg, 1.367 mmol), (2-(l- methyl-lH-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)boronic acid (Intermediate B, 443 mg, 1.640 mmol), potassium phosphate (1 160 mg, 5.47 mmol), and Pd(AmPhos)2Ci2 (Sigma- Aldrich, St. Louis, MO, 48.4 mg, 0.068 mmol). The vial was flushed with Ar (g), then dioxane (2928 mu) and water (976 mu) were added in sequence. The mixture was heated in a microwave reactor for 30 min at 90 C. After cooling to room temperature, the mixture was diluted with EtOAc, washed with water (and a small amount of brine to break up emulsions, 2x), washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was taken up in MeOH, then loaded onto a 10 g SCX-2 ion exchange column. The column was eluted with MeOH, then with 2M ammonia in MeOH. The basic filtrate was concentrated, and the residue was chromatographed on a 40 g silica gel column with 0 to 10% MeOH/DCM to provide 5-(2-(l -methyl- lH-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-l ,2,3,4- tetrahydroisoquinoline as a pale yellow solid. [M+H]+ = 358.1. XH NMR (400 MHz, DMSO-d6) delta ppm = 7.91 – 7.80 (m, 2 H), 7.56 (d, J= 8.0 Hz, 1 H), 7.28 (d, J= 2.0 Hz, 1 H), 7.09 – 6.95 (m, 2 H), 6.84 (dd, J= 1.3, 7.4 Hz, 1 H), 5.96 (d, J= 1.9 Hz, 1 H), 3.85 (s, 2 H), 3.52 (br. s., 3 H), 2.93 – 2.84 (m, 1 H), 2.79 – 2.67 (m, 1 H), 2.48 – 2.39 (m, 1 H), 2.09 (td, J= 5.3, 16.7 Hz, 1 H).

923591-51-9 5-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride 45074003, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; AMGEN INC.; DINEEN, Thomas; KREIMAN, Charles; WEISS, Matthew; GEUNS-MEYER, Stephanie; WO2013/134518; (2013); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1029689-82-4,Methyl 1,2,3,4-tetrahydroisoquinoline-8-carboxylate hydrochloride,as a common compound, the synthetic route is as follows.

To a solution of methyl 1,2,3,4-tetrahydroisoquinoline-8-carboxylate hydrochloride (12.37 g) and Example 1.1.10 (15 g) in dimethyl sulfoxide (100 mL) was added N,N-diisopropylethylamine (12 mL), and the mixture was stirred at 50 C. for 24 hours. The mixture was then diluted with ethyl acetate (500 mL) and washed with water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting with 20% ethyl acetate in hexane, to give the title compound. MS (ESI) m/e 448.4 (M+H)+., 1029689-82-4

The synthetic route of 1029689-82-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AbbVie Inc.; Benatuil, Lorenzo; Bruncko, Milan; Chao, Debra; Izeradjene, Kamel; Judd, Andrew S.; Phillips, Andrew C.; Souers, Andrew J.; Thakur, Archana; (556 pag.)US2017/355769; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 6-bromo-l,2,3,4-tetrahydroisoquinoline (100 mg, 0.472 mmol) and triethylamine (180 mu, 1.291 mmol) in anhydrous NMP (2.5 mL) was added to 2,4- dichloro-6-mophiholino-l,3,5-triazine (100 mg, 0.425 mmol). The reaction was flushed briefly with nitrogen, capped, stirred at room temp for 30 min at room temp, followed by heating at 80 C for 1 h. The crude reaction was purified via reverse phase Prep HPLC to afford 4-(4-(6-bromo-3,4-dihydroisoquinolin-2( lH)-yl)-6-chloro- l,3,5-triazin-2- yl)morpholine, 150 mg (86%). LCMS (M+l) = 410.1, 412.1. NuMuRhonu (500 MHz, (0186) DMSO-de) delta 7.48 – 7.35 (m, 2H), 7.24 (br dd, J=l 1.8, 8.3 Hz, 1H), 4.79 (br d, J=17.4 Hz, 2H), 3.90 (dt, J=14.6, 5.9 Hz, 2H), 3.76 (br s, 2H), 3.71 – 3.58 (m, 6H), 2.86 (br d, J=6.1 Hz, 2H).

226942-29-6, 226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6- isoquinolinecarboxylic acid (555 mg, 2 mmol), HATU (989 mg, 2.6 mmol), triethylamine (0.26 ml_, 2.6mmol) in DMF (15 ml.) and 5-{[(2-chlorophenyl)(methyl)amino]methyl}- 1 ,3,4-thiadiazol-2-amine (Intermediate 240) (509 mg, 2 mmol) was stirred at room temperature overnight. The DMF was evaporated under reduced pressure and the residue was dissolved in DCM. The organic phase was dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with a gradient DCM 100% to DCM/MeOH: 98/2. After evaporation of the right fractions, the material was triturated in hot methyl alcohol, to give after filtration and drying the title compound as a white solid (300 mg, 29%). HRMS calculated for C25H28CIN5O3S (M+H)+ 514.1680, found: 514.1651, Rt: 3.47 min.

170097-67-3, As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/104524; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem